Faeth Therapeutics Inc Ordinary Shares FTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
Trading Information
- Previous Close Price
- $19.92
- Day Range
- $20.20–20.46
- 52-Week Range
- $7.50–41.76
- Bid/Ask
- $20.05 / $20.58
- Shares Outstanding
- 25.84M
- Market Cap
- $521.01M
- Volume/Avg
- 1,902 / 362,820
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Valuation
Metric | FTH |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | FTH |
|---|---|
Quick Ratio | 15.84 |
Current Ratio | 16.12 |
Interest Coverage | — |
Quick Ratio
FTH
Profitability
Metric | FTH |
|---|---|
Return on Assets (Normalized) | −148.34% |
Return on Equity (Normalized) | −388.39% |
Return on Invested Capital (Normalized) | −389.47% |
Return on Assets
FTH
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|rgjGP! | LOCK|jdxw | $138B | |||
| Moderna Inc MRNA | LOCK|?>Yn$^J | LOCK|xK& | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|CXb!!<J | LOCK|<h!V | $93B | |||
| argenx SE ADR ARGX | LOCK|mNsMN>B | LOCK|P< | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|^^fQQG^ | LOCK|Yr | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|d@<fB&%k | LOCK|NTlF | $30B | |||
| Incyte Corp INCY | LOCK|F?h%&% | LOCK|%#r | $24B | |||
| BioNTech SE ADR BNTX | LOCK|G$FnC$< | LOCK|gQw | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|FP<x#C^ | LOCK|>$r? | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|?njRb# | LOCK|#$ | $15B |
United States